Bernard Emanuel O, Schmid Edith R, Schmidlin Daniel, Scharf Christoph, Candinas Reto, Germann Reinhard
Division of Cardiovascular Anesthesia, Institute of Anesthesiology, Raemistrasse 100, CH-8091 Zurich, Switzerland.
Crit Care Med. 2003 Apr;31(4):1031-4. doi: 10.1097/01.CCM.0000053555.78624.0F.
Ibutilide, a class III antiarrhythmic drug, has been shown to convert atrial fibrillation to sinus rhythm more rapidly than procainamide or sotalol. Our objective was to compare the efficacy and safety of ibutilide and amiodarone in patients after cardiac surgery.
Prospective, randomized, double-blinded study.
Intensive care unit of a university hospital.
Forty adults with an onset of atrial fibrillation within 3 hrs after admission.
Before the administration of antiarrhythmic drugs, a 24-hr Holter electrocardiograph was attached. Patients in the ibutilide group received ibutilide 0.008 mg/kg body weight over 10 mins; treatment was repeated if atrial fibrillation or flutter persisted. If sinus rhythm was not achieved within 4 hrs, amiodarone 5 mg/kg was administered over 30 mins, followed by amiodarone 15 mg/kg over 24 hrs. Patients in the amiodarone group received amiodarone 5 mg/kg over 30 mins, followed by amiodarone 15 mg/kg over 24 hrs if atrial fibrillation or flutter continued.
Within the first 4 hrs, atrial fibrillation was converted in nine of 20 patients (45%) in group ibutilide and in ten of 20 patients (50%) in group amiodarone (not significant). Mean time for conversion overall was 385 mins in group ibutilide and 495 mins in group amiodarone (not significant). In group amiodarone, the protocol was discontinued in two patients because of severe arterial hypotension. Atrial fibrillation recurred in 11 of 20 patients (55%) in group ibutilide and in seven of 20 patients (35%) in group amiodarone (not significant). Ventricular arrhythmia did not occur during the first 24 hrs of the protocol.
Ibutilide has no significant advantage over amiodarone for the conversion of atrial fibrillation to sinus rhythm in either time to conversion or conversion overall, but severe hypotension was not seen with ibutilide.
伊布利特是一种Ⅲ类抗心律失常药物,已证明其转复房颤为窦性心律的速度比普鲁卡因胺或索他洛尔更快。我们的目的是比较伊布利特和胺碘酮在心脏手术后患者中的疗效和安全性。
前瞻性、随机、双盲研究。
一所大学医院的重症监护病房。
40名入院后3小时内发生房颤的成年人。
在给予抗心律失常药物之前,连接24小时动态心电图仪。伊布利特组患者在10分钟内静脉注射伊布利特0.008mg/kg体重;如果房颤或房扑持续存在,则重复治疗。如果4小时内未转为窦性心律,则在30分钟内静脉注射胺碘酮5mg/kg,随后在24小时内静脉注射胺碘酮15mg/kg。胺碘酮组患者在30分钟内静脉注射胺碘酮5mg/kg,如果房颤或房扑持续,则在24小时内静脉注射胺碘酮15mg/kg。
在最初4小时内,伊布利特组20例患者中有9例(45%)房颤转复,胺碘酮组20例患者中有10例(50%)房颤转复(无显著差异)。伊布利特组总体转复平均时间为385分钟,胺碘酮组为495分钟(无显著差异)。在胺碘酮组,有2例患者因严重动脉低血压而终止治疗方案。伊布利特组20例患者中有11例(55%)房颤复发,胺碘酮组20例患者中有7例(35%)房颤复发(无显著差异)。在治疗方案的最初24小时内未发生室性心律失常。
在转复时间或总体转复方面,伊布利特在将房颤转复为窦性心律方面并不比胺碘酮有显著优势,但伊布利特未出现严重低血压。